You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation
|
|---|---|
| Published in |
Cancer Discovery, October 2018
|
| DOI | 10.1158/2159-8290.cd-17-1409 |
| Pubmed ID | |
| Authors |
Sean D. Reiff, Rose Mantel, Lisa L. Smith, J.T. Greene, Elizabeth M. Muhowski, Catherine A. Fabian, Virginia M. Goettl, Minh Tran, Bonnie K. Harrington, Kerry A. Rogers, Farrukh T. Awan, Kami Maddocks, Leslie Andritsos, Amy M. Lehman, Deepa Sampath, Rosa Lapalombella, Sudharshan Eathiraj, Giovanni Abbadessa, Brian Schwartz, Amy J. Johnson, John C. Byrd, Jennifer A. Woyach |
| Abstract |
Targeted inhibition of Bruton's tyrosine kinase (BTK) with the irreversible inhibitor ibrutinib has improved outcomes for patients with hematologic malignancies, including chronic lymphocytic leukemia (CLL). Here we describe preclinical investigations of ARQ 531, a potent, reversible inhibitor of BTK with additional activity against Src family kinases and kinases related to ERK signaling. We hypothesized that targeting additional kinases would improve global inhibition of signaling pathways, producing more robust responses. In vitro treatment of patient CLL cells with ARQ 531 decreases BTK-mediated functions including B cell receptor (BCR) signaling, viability, migration, CD40 and CD86 expression, and NF-κB gene transcription. In vivo, ARQ 531 was found to increase survival over ibrutinib in a murine Eμ-TCL1 engraftment model of CLL and a murine Eμ-MYC/TCL1 engraftment model resembling Richter's transformation. Additionally, ARQ 531 inhibits CLL cell survival and suppresses BCR-mediated activation of C481S BTK and PLCγ2 mutations which facilitate clinical resistance to ibrutinib. |
X Demographics
The data shown below were collected from the profiles of 23 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 8 | 35% |
| Japan | 2 | 9% |
| Saudi Arabia | 1 | 4% |
| United Kingdom | 1 | 4% |
| India | 1 | 4% |
| Unknown | 10 | 43% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 14 | 61% |
| Scientists | 3 | 13% |
| Science communicators (journalists, bloggers, editors) | 3 | 13% |
| Practitioners (doctors, other healthcare professionals) | 2 | 9% |
| Unknown | 1 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 78 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 78 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 15 | 19% |
| Researcher | 11 | 14% |
| Other | 8 | 10% |
| Student > Bachelor | 7 | 9% |
| Student > Master | 4 | 5% |
| Other | 7 | 9% |
| Unknown | 26 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 14 | 18% |
| Medicine and Dentistry | 14 | 18% |
| Chemistry | 9 | 12% |
| Immunology and Microbiology | 3 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
| Other | 8 | 10% |
| Unknown | 27 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 86. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 November 2023.
All research outputs
#477,070
of 24,837,702 outputs
Outputs from Cancer Discovery
#243
of 3,978 outputs
Outputs of similar age
#10,574
of 349,569 outputs
Outputs of similar age from Cancer Discovery
#12
of 103 outputs
Altmetric has tracked 24,837,702 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,978 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.5. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 349,569 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 103 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.